We wish all our partners and future partners, all our employees and future employees, and all their families a wonderful Christmas and a great start in 2017. Staburo will continue to support you with experienced biostatisticians and statistical programmers next year...

This talk provided insight into the system of the AMNOG and the hurdles which have to be overcome in the assessment of a benefit, with focus on the statistical needs. In particular, the process at the German authorities “Gemeinsamer Bundesausschuss” (G-BA) and...

This year's Staburo Christmas party took place in the Barschule München, where we learned very much about famous Cocktails, its variants and how to produce them. We started the course with (single-)blinded sensorical testing of different alcoholic analytes, by...

Staburo took part in the APF workshop on 25 November 2016 in Berlin. This year, the APF has been invited by Parexel International GmbH. The APF is a German pharmaceutical research working group for statisticians in the pharmaceutical and healthcare industry, academia...

Staburo took part in this year's BVMA symposium on 25 November 2016, at the Sheraton München Arabellapark Hotel, here in Munich. The BVMA represents the interests of the German CROs. The member companies maintain a lively exchange of information on all topics which...

In this talk, important aspects of pharmacokinetics (PK) and pharmacodynamics (PD) were presented. Four elements of PK (ADME) were discussed in detail. Biopharmaceutical classification system (BCS), 2-compartment distribution model, destructive and conjugative...

The website biologenkompass.de published a story about our Business Development Manager Roland Stieger (in German). The interview was done by Ulrike Herzog, who is one of the founders of biologenkompass.de. The goal of her team is to inform biologists with potential...

  Staburo took part in the 2016 BIO Europe Conference in Cologne between 7 and 9 November. The conference featured a wide range of interesting topics for statisticians in the pharmaceutical and healthcare industry, including health technology assessment,...

The incorporation of biomarkers into drug development becomes more and more important, as they provide essential information to find the right therapy at the right time for the right patient (“precision medicine”). This talk provided an overview on the roles of...